Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Amanda Knight
CONTACT
Arnavaz Eduljee
CONTACT
Lead
NanoCarrier Co., Ltd.
The first part of the study will determine the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and the recommended Phase 2 (RPII) dose of NC-6300. The second part of the study will assess the activity and tolerability of NC-6300 in patients with soft tissue sarcoma.
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted